Enriching Engineered T Cells with Antibody Sequencing & Modulation
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Amino acids are small organic molecules that make up peptides and proteins. All living organisms share the same set of amino acids. Amino acids come together in different orders (sequences) to form proteins. As such, each type of protein has a different three-dimensional structure and biological activity.
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.
Protein sequencing is a method that typically utilizes mass spectrometry (MS) to determine the amino acid code of a protein1. Prior to the development of mass spectrometry, Edman degradation, a method involving the stepwise degradation of peptides to derive the order of amino acids, was the mainstream approach. Nowadays, mass spectrometry is favored due to its ease of use and high throughput capabilities, though Edman degradation is still employed for specific applications in which the technique is well suited.
Monoclonal antibodies (mAbs) are homogenous antibodies that bind to a single epitope on an antigen. Kohler and Milstein generated the first mAbs when they developed hybridoma technology in the 1970s. Because of the specificity, homogeneity and unlimited availability, mAbs are valuable reagents used in a variety of important applications including treatment and diagnosis of diseases
Amino acids (aa)—the building blocks of proteins—are simple molecules characterized by a variable R group flanked either side by an amino group and a carboxyl group. With around 20 different commonly found amino acids, each one can bond with another to produce chains that can be classified as peptides (typically below 50 aa) and proteins (sequences above 50 aa)—molecules ubiquitous to every known organism.
Amino acid sequencing is commonly performed using Edman degradation or mass spectrometry (MS). While mass spectrometry is favoured for its high throughput capabilities and ease of use, both techniques possess their own features and limitations. This article summarizes some of the key pain points inherent in the two methodologies when determining the amino acid sequence.
Antibodies are used in a variety of ways in academia and industry, from tools to therapeutics. Because antibodies are produced using live processes, which are naturally error-prone, validation is required from time to time. Furthermore, to develop biological therapeutics, the protein sequence must be confirmed as part of the regulatory process.
Written by Yuning Wang, PhD August 1, 2021 What is DNA Sequencing? DNA sequencing is the process of determining the precise order of four nucleotides bases—adenine (A), guanine (G), cytosine (C), and thymine (T)—that make up the DNA molecule. From Sanger sequencing to next-generation sequencing (NGS), DNA sequencing’s accessibility and ease [...]
Written by María Gerpe, PhD July 23, 2021 Why the Amino Acid Sequence Matters As proteins are assembled, they fold into different structural orders: from primary to quaternary. The exact sequence of the primary structure (the amino acid sequence) will dictate how a protein will fold and therefore function. The importance of [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Proteins are composed of peptide chains, which in turn are made up of a string or linear sequence of amino acids (Figure 1A). Every amino acid has a basic structure containing an amino (-NH2) group and a carboxylic (-COOH) group (Figure 1B). To form a peptide, amino acids link to each other via a peptide bond, which involves the reaction between the carboxylic group of one amino acid and the amine group of another amino acid (Figure 1B). As such, the primary structure of a protein is typically recorded starting at the amino-terminal (N) end and continuing to the carboxyl-terminal (C) end. The primary protein structure may be directly sequenced from a sample of the protein itself or inferred from the DNA sequence.
Protein mass spectrometry refers to the use of mass spectrometry in the study and characterization of proteins, including their quantification, profiling, interaction mapping, and identification of their post-translational modifications (1,2). Protein mass spectrometry may also be referred to as mass spectrometry-based proteomics. Mass spectrometry-based proteomics consist of three approaches: top-down, middle-down, and bottom-up proteomics
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Team Rapid Novor will be attending PEGS Europe, 12 -16 November 2018, Lisbon Congress Center, Lisbon, Portugal. Booth #208 Our co-founder and CEO, Mingjie, will speak at the conference. He will talk about the goal, the challenges and our REmAb™ approach towards antibody protein sequencing. We have recently accelerated our sequencing project delivery timeline and reduced the amount of mAb protein samples [...]
Team Rapid Novor will be touring Europe in the next several weeks. The first conference is the European Antibody Congress, 29 – 31 October 2018, Congress Centre, Basel, Switzerland. Booth #18. At the conference, our co-founder and CEO, Mingjie, will talk about the goal, the challenges and our REmAb™ approach towards antibody protein sequencing. He will share in greater details the experiences and [...]
Rapid Novor is bringing WILD™ to the wild WILD West June 3rd to 8th for ASMS in San Diego, California. We will setup our base at booth # 1018 and share with you our latest development on the accurate determination of Isoleucine and Leucine using mass spectrometry experiments while sequencing antibody proteins. We will also [...]
We are busy packing our baggages for the upcoming PEGS Boston conference April 30 - May 4, at Seaport World Trade Center in Boston, MA. PEGS: The Essential Protein Engineering Summit is one of the most prestige and preeminent events we go to every year. In this year's meeting, our co-founder and CEO, Mingjie, will give a [...]
Rapid Novor is exhibiting at the Molecular Med Tri-CON this week at The Moscone South Convention Center, San Francisco, California. Please visit our booth #533 and learn how our REmAb™ antibody protein sequencing solution may help in your research.
Rapid Novor will be attending Peptalk 2018 conference January 8 - 12, at Hilton San Diego Bayfront, San Diego, California. Our co-founder and CEO, Mingjie, will give a talk at 11:30am on Thursday. Mingjie will talk about the goal, the challenges and our approach in developing REmAb™, the world's most advanced antibody protein sequencing platform. He [...]
The Novor team will be flying into Boston again next week attending the Discovery on Target conference. On Wednesday morning, Mingjie, our co-founder and CEO, will give a talk on the topic of Sequencing Antibody Proteins with Mass Spectrometry. Mingjie will share the best practices we developed during our journey sequencing hundreds of antibody proteins [...]
At Rapid Novor, we constantly look for ways to deliver our REmAb™ service better, quicker and more consistent. We believe automation, both in the lab and in the data analysis platform, is crucial to meet our clients' ever evolving requirements on service throughput and quality. Today, we have our first pipetting robot from Opentrons installed [...]
As you may have already known, Rapid Novor is a world leader in the antibody/protein sequencing business. But, what you should also know is that we pride ourselves on the unique R&D capability of advancing new technologies and scientific breakthroughs in the field of protein sequencing with mass spectrometry. We believe that the game-changing technologies [...]
The Novor Team is heading to San Diego to attend the largest, most influential biotech Convention, BIO 2017, June 19-22, 2017. We are excited to show case our ground breaking antibody protein sequencing technology at booth #5227, in the Discovery Zone, in Hall G. Different from the traditional DNA sequencing technology, we directly sequence the antibody protein [...]
It is the time of the year scientists around the world working with mass spectrometry get together exchanging ideas and celebrating achievements. Scientists from the Novor team will RACE to Indy this weekend to join the celebration. And here is the plan. :) Looks like there are quite a bit of obstacles we need to [...]
The Novor team will once again attending the prestige PEGS Boston conference hosted at the Seaport World Trade Center in Boston, May 1 to 5, 2017. With the successful completion of over 100 sequencing projects in the past 12 months, we are proud to share the experiences and best practices we have developed during our [...]
The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. The Novor team is thrilled to be part of this event from April 1-5, 2017 at the Walter E. Washington Convention Center, Washington, D.C. Antibodies are widely used in cancer research and treatment. Rapid Novor provides the technologies [...]
The Novor team is going back to China attending two prestige conferences, PEGS China in Shanghai (March 28 - 30) and International Congress of Antibodies (ICA2017) in Beijing (March 29 - 31). Our co-founder and CEO, Mingjie, will give a talk at ICA2017 on March 30. He will briefly talk about the antibody protein sequencing and then [...]
We planned long and hard for a great start of 2017. From January 9 to 13, the Novor team will be at the PepTalk conference hosted at Hilton San Diego Bayfront, San Diego, California. We are thrilled to have the opportunity to share our experiences and best practices we developed during our journey in session T5A: Characterization [...]
The Novor team is on their way to this year's PEGS Europe conference, from October 31 to November 4, at EPIC SANA Lisbon Hotel, Lisbon, Portugal. We are honored to have the opportunity to present our works in the Engineering Antibodies session at 12:45pm, Wednesday, November 2. Our co-founder, Mingjie, will deliver the presentation, Antibody [...]
Rapid Novor Inc is proud to be an invited participant of the GBSI's Antibody Validation Workshop, taking place at the Asilomar Conference Grounds from September 25 to September 27, 2016. We are thrilled to be part of this prestigious group of thought leaders and industry experts for a better future of antibodies. The workshop will [...]
This year's International Mass Spectrometry Conference is in our home base, the beautiful and dynamic city of Toronto. The Novor team is prepared to present its unparalleled de novo sequencing capability and share some of the stories and lessons learned on antibody protein sequencing. We invite you for a discussion at our booth #1416. You [...]
It is the time of the year again that scientists around the world get together and discuss interesting and cutting edge scientific ideas, processes and applications. Rapid Novor is no exceptions and we are heading to San Antonio in only a few weeks time. We invite you to the Novor booth #206 for a brief chat [...]
On May 19 and 20, the Novor team will be attending Americas Antibody Congress at Hilton San Diego Resort and Spa, San Diego, CA. The conference is co-hosted with World Biosimilar Congress and Cell Culture World Congress. We invite you for a brief chat with our founders and see in action why REAL de novo antibody protein sequencing is critical [...]
We will showcase our antibody protein characterization solution at PEGS Boston 2016, April 25 - 29, at Seaport World Trade Center in Boston, MA. Here are the things we can help you with: Restores your hybridoma cell line Confirms your antibody product Accelerates biosimilar development We invite you for a brief chat at our booth [...]
The Novor team will be attending the US HUPO conference from March 13 - 16 in Boston. Please come visit us at booth #2 to learn details about our Antibody Protein Sequencing technology. If you would like to arrange a private meeting, please email us at support@rapidnovor.com. See you in a week!
The topic of this year's ASMS Sanibel Conference is Characterization of Protein Therapeutics by Mass Spectrometry. It is a great fit for us to talk about our Antibody Protein Sequencing Service. Built on the superior Novor de novo sequencing engine, we are developing an automated protein sequencing platform to help speed up antibody drug development. The [...]
Come meet the Novor team at booth #108 during HUPO 2015, September 27 – 30, 2015, Vancouver Convention Center, Vancouver, British Columbia, Canada. What's New? At this year's HUPO, we will be announcing the following new advancements in the Novor software. Novor Cloud now works with Dropbox Novor now supports high resolution MS/MS data Novor now works [...]
Monday Poster 439, ASMS 2015 While Novor is a novel tool, we are no strangers to the community. Please visit poster 439 on Monday and chat with our founders. We are thrilled to share with you the ground breaking new approach as well as our excitement. Novor: Real-Time Peptide de Novo Sequencing Novor @ ASMS [...]